Información de Vertex Pharmaceuticals Inc, dividendo de Vertex Pharmaceuticals Inc, actividades de los accionistas y más

Más Datos de Vertex Pharmaceuticals Inc Compañía

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.

Información de Vertex Pharmaceuticals Inc



Símbolo de cotizaciónVRTX

Nombre de la empresaVertex Pharmaceuticals Inc

Fecha de salida a bolsaJul 24, 1991

Director ejecutivoDr. Reshma Kewalramani

Número de empleados6100

Tipo de seguridadOrdinary Share

Fin del año fiscalJul 24

Dirección50 Northern Avenue

CiudadBOSTON

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal02210

Teléfono16173416393

Sitio Webhttps://www.vrtx.com/

Símbolo de cotizaciónVRTX

Fecha de salida a bolsaJul 24, 1991

Director ejecutivoDr. Reshma Kewalramani

Ejecutivos de Vertex Pharmaceuticals Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

51.81K

+23.92%

Mr. Bruce I. Sachs

Lead Independent Director

45.00K

+12.50%

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.67K

+40.46%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

30.30K

+19.95%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

24.47K

--

Mr. Duncan Mckechnie

Executive Vice President, Chief Commercial Officer

16.13K

--

Mr. Jonathan Biller, J.D.

Executive Vice President, Chief Legal Officer

15.65K

-11.09%

Mr. Lloyd A. Carney

Independent Director

7.12K

+12.60%

Dr. Sangeeta N. Bhatia, M.D., Ph.D.

Independent Director

4.57K

-5.51%

Ms. Jennifer J. Schneider

Independent Director

1.72K

+86.33%

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

51.81K

+23.92%

Mr. Bruce I. Sachs

Lead Independent Director

45.00K

+12.50%

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.67K

+40.46%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

30.30K

+19.95%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

24.47K

--

Mr. Duncan Mckechnie

Executive Vice President, Chief Commercial Officer

16.13K

--

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de oct

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Por negocioUSD

Nombre

Ganancia

Proporción

TRIKAFTA

2.55B

86.65%

Other product revenues

205.70M

6.99%

ALYFTREK

156.80M

5.33%

CASGEVY

30.40M

1.03%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

1.83B

62.08%

Europe

910.90M

30.94%

Other

205.60M

6.98%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

TRIKAFTA

2.55B

86.65%

Other product revenues

205.70M

6.99%

ALYFTREK

156.80M

5.33%

CASGEVY

30.40M

1.03%

Estadísticas de accionistas

Actualizado: dom., 17 de ago

Accionistas

Tipos de accionistas

Accionistas

Proporción

Capital World Investors

11.21%

The Vanguard Group, Inc.

9.31%

Capital Research Global Investors

6.28%

BlackRock Institutional Trust Company, N.A.

5.52%

State Street Investment Management (US)

4.59%

Otro

63.09%

Accionistas

Proporción

Capital World Investors

11.21%

The Vanguard Group, Inc.

9.31%

Capital Research Global Investors

6.28%

BlackRock Institutional Trust Company, N.A.

5.52%

State Street Investment Management (US)

4.59%

Otro

63.09%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

60.58%

Investment Advisor/Hedge Fund

27.28%

Research Firm

2.54%

Pension Fund

2.27%

Bank and Trust

2.01%

Sovereign Wealth Fund

1.49%

Hedge Fund

0.70%

Individual Investor

0.14%

Insurance Company

0.12%

Otro

2.88%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

2924

248.95M

97.09%

-3.97M

2025Q2

2933

252.71M

98.56%

+2.47M

2025Q1

2977

252.24M

98.22%

-39.54K

2024Q4

2877

248.76M

96.87%

-2.25M

2024Q3

2786

247.87M

96.18%

-4.19M

2024Q2

2747

248.36M

96.27%

-4.14M

2024Q1

2680

247.63M

95.87%

-4.48M

2023Q4

2608

247.92M

96.20%

-4.51M

2023Q3

2477

248.64M

96.45%

-6.19M

2023Q2

2488

248.89M

96.55%

-7.11M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Capital World Investors

28.73M

11.21%

+198.84K

+0.70%

Jun 30, 2025

The Vanguard Group, Inc.

23.86M

9.31%

+479.23K

+2.05%

Jun 30, 2025

Capital Research Global Investors

16.11M

6.28%

+1.57M

+10.81%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

14.15M

5.52%

+156.31K

+1.12%

Jun 30, 2025

State Street Investment Management (US)

11.78M

4.59%

-13.43K

-0.11%

Jun 30, 2025

Fidelity Management & Research Company LLC

6.30M

2.46%

-1.32M

-17.28%

Jun 30, 2025

Geode Capital Management, L.L.C.

5.93M

2.31%

+166.99K

+2.90%

Jun 30, 2025

Invesco Capital Management (QQQ Trust)

5.26M

2.05%

-18.59K

-0.35%

Aug 31, 2025

Wellington Management Company, LLP

4.81M

1.88%

-641.36K

-11.76%

Jun 30, 2025

AllianceBernstein L.P.

4.38M

1.71%

+424.81K

+10.75%

Jun 30, 2025

ETFs relacionados



Actualizado: sáb., 1 de nov

Nombre

Proporción

VanEck Biotech ETF

9.42%

ProShares Ultra Nasdaq Biotechnology

8.56%

Invesco Nasdaq Biotechnology ETF

8.38%

iShares Biotechnology ETF

7.31%

Invesco Biotechnology & Genome ETF

4.96%

Natixis Loomis Sayles Focused Growth ETF

3.75%

First Trust NASDAQ Pharmaceuticals ETF

3.68%

Franklin Genomic Advancements ETF

2.99%

ETC 6 Meridian Quality Growth ETF

2.96%

Global X Genomics & Biotechnology ETF

2.83%

VanEck Biotech ETF

Proporción9.42%

ProShares Ultra Nasdaq Biotechnology

Proporción8.56%

Invesco Nasdaq Biotechnology ETF

Proporción8.38%

iShares Biotechnology ETF

Proporción7.31%

Invesco Biotechnology & Genome ETF

Proporción4.96%

Natixis Loomis Sayles Focused Growth ETF

Proporción3.75%

First Trust NASDAQ Pharmaceuticals ETF

Proporción3.68%

Franklin Genomic Advancements ETF

Proporción2.99%

ETC 6 Meridian Quality Growth ETF

Proporción2.96%

Global X Genomics & Biotechnology ETF

Proporción2.83%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos